Global Search

Hide Filters

Showing 1765 results

Press release / Sep 12, 2018

Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents with MS

Treatment with Gilenya (fingolimod) substantially reduced the debilitating impact of MS, with significant decreases in key measures of disease activity vs. interferon beta-1a MS severely affects…
Migraine
Press release / Nov 29, 2018

Novartis announces EU approval of Gilenya® for children and adolescents with MS, making it the first and only oral disease-modifying treatment for these patients in Europe

Approval based on landmark PARADIGMS study showing Gilenya (fingolimod) significantly reduced relapse rates by 82% vs interferon beta-1a; additionally, 85.7% of Gilenya patients were relapse-free…
Press release / Jul 02, 2019

Sandoz launches oncology generic gefitinib in 13 EU countries at loss of market exclusivity, expanding access to essential medicine

Sandoz gefitinib indicated for adult patients with locally advanced or metastatic non-small cell lung cancer[1] with activating mutations of EGFR-TK[1] More than 300,000 European men and women…
Press release / Nov 07, 2022

Sandoz announces further investment in key manufacturing facility in Austria, to support increased global demand for essential antibiotics

EUR 50m planned investment to support increased manufacturing capacity for finished dosage form penicillins, the leading class of antibiotics worldwideNew project brings total planned investment into…
Press release / Mar 03, 2020

International research partnership and EDCTP to invest €44m in next-generation antimalarials to combat drug-resistant malaria in Africa

EDCTP grants the PAMAfrica research consortium €21.9 million over a 5 year period; MMV, Novartis and other partners will provide an additional €22 million. The PAMAfrica consortium brings…
Press release / Oct 21, 2015

Novartis broadens immuno-oncology pipeline with acquisition of Admune Therapeutics and licensing agreements with XOMA and Palobiofarma

With four programs currently in clinical trials and five more expected to enter the clinic by the end of 2016, Novartis has rapidly built a robust portfolio of programs focused on stimulating the…
Press release / Sep 03, 2016

Novartis' Ultibro® Breezhaler® consistently more effective than Seretide®* in reducing COPD flare-ups across different patient groups

Ultibro® Breezhaler® reduced rate of all COPD exacerbations across different patient sub-groups vs Seretide® in new analyses from FLAME study Analyses show that Ultibro Breezhaler lowered…
Press release / Dec 16, 2016

Novartis drug Votubia® recommended by CHMP for EU approval to treat refractory partial-onset seizures in patients with TSC

If approved, Votubia would be the first adjunctive treatment specifically for refractory seizures in children and adults with tuberous sclerosis complex (TSC)[1] Seizures are the most…
Press release / Jul 30, 2018

Novartis marks a new era for migraine patients with the EU approval of Aimovig®, a first-of-its-kind treatment specifically designed for migraine prevention

Patients on Aimovig (erenumab) in clinical trials reported consistent and sustained migraine prevention, with many experiencing a 50% or more reduction in monthly migraine days; safety and…